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Summary From 1979-1983, 299 patients with stage III or IV Hodgkin's disease (HD) were randomised to
receive cyclical chemotherapy with MOPP (mustine, Oncovin, procarbazine, prednisone) or LOPP (Leukeran
substituted for mustine). Two hundred and ninety patients were evaluable. There was no statistically
significant difference between the complete remission (CR) rates (63% for MOPP, 57% for LOPP), percentage
of patients remaining disease free at 5 years (38% for MOPP, 35% for LOPP) and overall survival at 5 years
(65% for MOPP, 64% for LOPP). On multivariate analysis younger age, grade I histopathology, absence of
systemic symptoms, and normal albumin level were favourable prognostic factors for survival.
Acute toxicity in the form of nausea/vomiting, myelosuppression, and phlebitis were less with LOPP than
MOPP. Deaths in both groups were usually due to disseminated Hodgkin's disease; there were no infective
deaths in the absence of Hodgkin's disease. Second malignancies occurred in six patients treated with MOPP -
three acute myeloid leukaemia (AML), one non-Hodgkin's lymphoma (NHL), two carcinomas (Ca); with
LOPP, four second malignancies occurred (one AML, one NHL, two Ca). These long term results confirm
that LOPP is as effective as MOPP, and less toxic, in the treatment of advanced Hodgkin's disease.
In the 1970's it was established that cyclical combination
chemotherapy (MOPP or MVPP) was effective treatment for
advanced Hodgkin's disease (De Vita et al., 1970; Nicholson
et al., 1970). Remission rates of above 75% have been
obtained with MOPP and over half of such patients have
remained in long-term remission (Longo et al., 1986). How-
ever, MOPP and MVPP proved toxic, particularly with
regard to the mustine, which caused considerable nausea and
vomiting and a high incidence of local tissue reactions (par-
ticularly phlebitis). The substitution of chlorambucil (Leu-
keran) appeared to give equally favourable results with less
toxicity (McElwain et al., 1977). Long term follow-up of the
Royal Marsden Hospital data reported in this Journal
confirms this early conclusion (Selby et al., 1990). Between
1979 and 1983 the British National Lymphoma Investigation
(BNLI) conducted a randomised multicentre study of MOPP
against LOPP (Leukeran substituted for mustine) and re-
ported that LOPP appeared to be as effective as MOPP and
less toxic (Hancock, 1986). Long-term results of this study
are reported here.
Methods
Patient selection
The criteria for inclusion were as follows:
(1) Opportunity for adequate long-term follow-up must
have been anticipated.
(2) Freedom from any other known serious disease
which might severely limit the patient's life expectancy.
(3) No previous chemotherapy and/or radiotherapy
except as an emergency measure for obstructive symp-
toms.
(4) Surgical staging was not required but all patients
were required to have either lymphangiography or CT
scanning of the abdomen.
(5) Histopathological diagnosis confirmed by the BNLI
histopathology panel.
A total of 299 patients staged III or IV were initially
included: of these 157 were randomised to MOPP, 142 to
LOPP. Seven patients in the MOPP arm and two patients in
the LOPP arm were excluded, due to histopathological re-
vision, inadequate staging, or lack of follow-up, leaving 150
patients in the MOPP and 140 patients in the LOPP arm
available for this present analysis. Protocol violation occur-
red in four cases: one patient randomised to MOPP received
LOPP, and three randomised to LOPP received MOPP.
Stratification was by age, sex, stage, pathology grade and
laparotomy status. The pathology grade was defined by
BNLI criteria (Bennett et al., 1985). The patient characteris-
tics of the groups analysed for survival are shown in Table I.
A minimum of six cycles of each regimen (see Appendix) was
given to responding patients, with the proviso that at least
three cycles of treatment were given following initial com-
plete response. Patients not responding were treated off pro-
tocol. By BNLI criteria complete remission (CR) was defined
as complete disappearance of all disease for a minimum of 3
months after completion of treatment, with normalisation at
this time of CT scans and of any other initially abnormal
investigations.
Multivariate analyses were made using the Cox model
(Cox, 1972). Survival curves were calculated by the life table
method and statistical comparison of curves carried out by
the log rank test as described by Peto et al. (1977) and by the
Mantel test (1966).
The deaths of patients who remained in complete remis-
sion from their first course of treatment until their time of
death who died from causes other than HD were censored in
the disease-free and relapse-free curves, but were included in
the curve for overall survival.
Results
The percentage of patients who achieved complete remission
(CR) from initial MOPP was 63%, and from initial LOPP
was 57%: the percentage of these patients remaining relapse-
free at 5 years was 61% for both MOPP and LOPP (Figure
1). Freedom from HD at 5 years was 38% for MOPP and
35% for LOPP (Figure 2). The overall survival (OS) at 5
Correspondence: G. Vaughan Hudson.
Received 7 September 1990; and in revised form 20 November 1990.
Br. J. Cancer (1991), 63, 579-582 '." Macmillan Press Ltd., 1991580 B.W. HANCOCK et al.
Table I Characteristics of those patients analysed for survival
Frequency
MOPP LOPP
Total 150 (100%) 140 (100%)
Age (years) 15-49 110 (73.3%) 101 (72.1%)
> 50 40 (26.7%) 39 (27.9%)
Sex Male 100 (66.7%) 97 (69.3%)
Female 50 (33.3%) 43 (30.7%)
Mediastinal No 71 (48.3%) 81 (60.4%)
involvementa Yes 76 (51.7%) 53 (39.6%)
Stage III 78 (52.0%) 74 (52.9%)
IV 72 (48.0%) 66 (47.1%)
Symptoms A 66 (44.0%) 66 (47.1%)
B 84 (56.0%) 74 (52.9%)
Stage IIIA 43 (28.7%) 41 (29.3%)
IIIB 35 (23.3%) 33 (23.6%)
IVA 23 (15.3%) 24 (17.1%)
IVB 49 (32.7%) 42 (30.0%)
Pathology grade (BNLI) 1 72 (48.0%) 53 (37.9%)
2 77 (51.3%) 86 (61.4%)
Other 1 ( 0.7%) 1 ( 0.7%)
ESR (mm h-1)a <40 56 (43.4%) 54 (45.8%)
> 40 73 (56.6%) 64 (54.2%)
Albumin (g litre-I)a < 36 41 (29.3%) 31 (24.8%)
36 91 (70.7%) 94 (75.2%)
Laparotomya Yes 43 (28.9%) 37 (26.8%)
No 106 (71.1%) 101 (73.2%)
aPercentage of the total where factor was recorded.
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Figure 1 Patients achieving complete remission from initial
treatment. Percentage remaining relapse-free at 5 years: MOPP
61.3% ± 5.1% (s.e.), LOPP 61.2% ± 5.5% (s.e.).
Figure 3 All patients. Overall survival at 5 years: MOPP
65.1% ± 3.9% (s.e.), LOPP 63.5% ± 4.1% (s.e.).
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Figure 2 All patients. Overall percentage remaining relapse free
at 5 years: MOPP 38.4% ± 4.0% (s.e.), LOPP 35.0% ± 4.0%
(s.e.).
years was 65% for MOPP and 64% for LOPP (Figure 3).
There was no significant difference between MOPP and
LOPP for any of these results (P= 0.4, 0.61, 0.3 and 0.98
respectively).
CR was achieved in a further nine patients treated with
MOPP, and a further 12 treated with LOPP, after additional
treatment with radiotherapy (RT) for residual disease. The
overall CR rates, including RT to residual nodal masses, are
thus 69% and 65% in the MOPP and LOPP arms respec-
tively.
Prognosticfactors (multivariate analysis)
A multivariate analysis was performed on the overall series,
using the Cox model. The variables included were the presen-
tation age, sex, stage, symptoms, histological subtype, media-
stinal status (involved/not involved), lymphocyte count,
albumin and haemoglobin levels, and erythrocyte sedimenta-
tion rate (ESR).
For overall survival the significant prognostic factors were
age, pathology, symptoms and albumin level, with increased
age, grade 2 pathology, 'B' symptoms and low albumin level
being associated with poorer survival (Table II). When the
treatment allocation was included with these factors, the
estimated relative risk (LOPP to MOPP) was 1.01 with 95%
confidence interval 0.70 to 1.48.
For overall percentage of patients remaining disease-free,
only stage and symptoms were found to be significant prog-
nostic factors, patients with stage IV and 'B' symptoms
faring worse.
For patients achieving CR, sex and symptoms were found
to be significant factors influencing subsequent relapse, with
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Table II Major prognostic factors
CR relfree Diseasefree Overall survival
Age Z = 3.69
Sex Z = 2.14
Stage Z = 2.23
Symptoms Z = 1.98 Z = 3.35 Z = 2.83
Histology Z = 2.37
Albumin level Z= 2.55
Z = ratio of regression coefficient to its standard error.
males and patients with 'B' symptoms tending to have
shorter periods in CR before relapsing.
Acute toxicity
Acute toxicity data were given in the initial BNLI report
(Hancock, 1986). In summary, nausea/vomiting, myelosup-
pression and phlebitis were all significantly less in the LOPP
group compared with MOPP.
Major dose modifications (more than half dose reduction
on two or more occasions) or delays in start of course of
treatment (more than 1 week on two or more occasions) were
required, usually on the basis of myelosuppression, in 15
patients having MOPP (10%) and in ten patients receiving
LOPP (7%).
Second malignancy
Second malignancies were seen in six patients treated with
initial MOPP (three acute myeloid leukaemias (AML), one
non-Hodgkin's lymphoma (NHL), two carcinomas (Ca));
with initial LOPP four second malignancies were seen (one
AML, one NHL, two Ca).
Mortality
There were 63 deaths in the MOPP arm and 59 in the LOPP
arm (Table III). Death in both groups was mostly related to
disseminated HD, often with terminal infection, but in the
MOPP arm five patients died from second malignancies, and
in the LOPP arm three: six of these eight patients were in CR
from their HD at time of death. A further eight deaths
occurred in CR: one in the LOPP arm (myocardial infarct),
and seven in the MOPP arm (two myocardial infarcts, one
idiopathic thrombocytopenic purpura, one pneumonia, one
congestive heart failure, one motor neurone disease, one road
traffic accident).
Discussion
The complete remission rates reported here with MOPP and
LOPP chemotherapy in Stage III/IV Hodgkin's disease (71%
clinically staged) are almost identical, as are the percentages
of patients remaining disease free and the overall survival up
to 10 years.
The results obtained with MOPP are in line with the
previous BNLI experience. In 532 patients who received
initial MOPP chemotherapy the CR rate was 61% with an
overall survival at 10 years of 52%. In the 369 patients with
Stage IIIB/IV disease, the CR rate was 59% with an overall
survival at 5 and 10 years of 62% and 47% respectively.
The CR rates reported here with MOPP and LOPP are less
than those reported in the initial MOPP study from the NCI
(Longo et al., 1986) and the ChlVPP study reported from the
Royal Marsden Hospital (Selby et al., 1990). In the latter
series of 284 patients with Stages I and IT (poor prognosis)
and III and IV Hodgkin's disease, 85% of the 229 previously
Table III Causes of death
Total deaths HD related 2nd malignancies Other causes
MOPP 63 51 5 7
LOPP 59 55 3 1
untreated patients attained CR after chemotherapy. Of these
patients additional radiotherapy was given to 128 patients.
Seventy-four percent remained in complete remission at 5
years and 71% at 10 years and the overall survival was 73%
and 65% at 5 and 10 years respectively.
Several possibilities exist for the apparent differences be-
tween these reports. Firstly the patient selection may differ.
Only 29% of the patients reported in the BNLI study were
pathologically staged compared to 45% in the Marsden
series. All the patients in the BNLI study were Stage III or
IV, but the same is true of the NCI cohort and, if one looks
only at the clinically staged III and IV patients in the Mars-
den series the CR rate is still higher at 79%. The dosages of
chlorambucil and of procarbazine in the BNLI LOPP regime
were less than that in the Marsden ChlVPP regime and this
may have accounted for the lower response rate. Alterna-
tively there may be significant differences between series in
the criteria for definition of CR.
If one by contrast looks at overall survival then there is
remarkable conformity of results. In the NCI MOPP study
the 10 year survival was 52% which is identical to the BNLI
experience. The LOPP data in this paper shows a 5 year
overall survival of 64% and an approximate value of 55% at
10 years, which is similar to the 62% at 10 years for Stage
III/IV patients reported in the Marsden series for ChlVPP.
For Stage IV patients the overall survival at 5 years was 65%
in both series.
Implicit in the fact that a lower CR has been reported with
a similar overall survival is that successful salvage therapy
has been possible. In this context it is worth noting that 57 of
the 290 patients relapsed or had residual disease in nodal
areas and were treated with radical radiotherapy. Of these,
37 are alive and 24 remain disease free following radio-
therapy. It is also possible that patients treated less inten-
sively with first line chemotherapy are more amenable to
salvage with second line chemotherapy.
Multivariate analysis confirms the importance of prognos-
tic factors in influencing survival data; for example, in our
study overall survival was significantly worse for older age,
unfavourable histology, 'B' symptoms and low albumin.
These findings are broadly consistent with those reported for
other chemotherapy regimens (reviewed by Selby et al.,
1987).
Substitution of chlorambucil for mustine in 'standard'
quadruple chemotherapy represents a considerable advance
in terms of improving patients' quality of life. However a
large proportion of patients fail with such therapies alone
and there is clearly a need for developing new strategies.
Alternating or hybrid regimens, or using high dose chemo-
therapy (with or without autologous bone marrow trans-
plant) may improve the outlook and the BNLI is currently
evaluating such approaches in randomised studies.
The BNLI would like to thank the collaborators from the referring
centres whose patients are included in this analysis. We are grateful
for financial help from The Cooperative Clinical Cancer-therapy
Trust Fund, The Cancer Research Campaign, The Lisa Lear Fund
and The Isle of Man AntiCancer Association.
Appendix
MOPP
Mustine, 6mg m2, maximum 15 mg, i.v. - days 1 and 8; Vincris-
tine*, 1.4 mg m-2, maximum 2 mg, i.v. - days 1 and 8; Procarbazine,
100 mg m-2, maximum 200 mg, orally daily for 10 days; Prednisone
(or prednisolone), 25mgm2, maximum 60 mg, orally daily for 14
days.
28 day cycle
LOPP
As for MOPP, but Leukeran (chlorambucil) 10mg daily orally for
10 days substituted for mustine.
*Vinblastine (6mgm-2, maximum 10 mg) substituted for vincristine
when neuropathy troublesome.582 B.W. HANCOCK et al.
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